Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2018, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.
Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 10, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 6 and 4 molecules, respectively.
Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note : Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Primary Immune Deficiency (PID) - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) - Overview
Primary Immune Deficiency (PID) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Primary Immune Deficiency (PID) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
ADMA Biologics Inc
Biotest AG
Casebia Therapeutics
Genethon SA
GigaGen Inc
GlaxoSmithKline Plc
Green Cross Corp
Leadiant Biosciences Inc
Novartis AG
Octapharma AG
ProMetic Life Sciences Inc
Sangamo Therapeutics Inc
Shire Plc
Taiga Biotechnologies Inc
Therapure Biopharma Inc
UCB SA
X4 Pharmaceuticals Inc
Primary Immune Deficiency (PID) - Drug Profiles
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Primary Immune Deficiency Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elapegademase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seletalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Hematological Disorders and Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate IL-2 Gamma Receptor for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Strimvelis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBX-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-4P001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Product Development Milestones
Featured News & Press Releases
Nov 22, 2017: Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
Nov 06, 2017: Shire to Present New Data on the Treatment of Primary Immunodeficiency
Oct 23, 2017: Shire to Present New Data on Immune Globulin Research at ACAAI 2017 Annual Scientific Meeting
Nov 23, 2016: Green Cross Receives Complete Response Letter from US FDA for IVIG-SN
Sep 23, 2016: Shire to showcase data on HyQvia during European Society for Immunodeficiencies Biennial Meeting
Aug 09, 2016: ProMetic Completes Adult Patients Enrolment in Pivotal IVIG Phase 3 Clinical Trial
Jul 21, 2016: Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe
May 02, 2016: Baxalta Receives Positive Opinion from Europe's CHMP for HYQVIA to Treat Pediatric Patients
Mar 07, 2016: Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10%
Mar 03, 2016: Baxalta to present on HYQVIA at 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting
Jan 25, 2016: US FDA Accepts Green Cross' Biologics License Application for IVIG-SN
Dec 02, 2015: Baxalta Receives CHMP Positive Opinion on HYQVIA
Nov 24, 2015: Green Cross Submits Biologics License Application to US FDA for IVIG-SN
Oct 26, 2015: Prometic's IVIG IND Cleared By FDA
Aug 03, 2015: Baxalta Announces Expanded CMS Coverage for Medicare PI Patients to Receive At-Home Treatment with HYQVIA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Primary Immune Deficiency (PID), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Casebia Therapeutics, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Genethon SA, H1 2018
Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Green Cross Corp, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Leadiant Biosciences Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Novartis AG, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2018
Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Shire Plc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Therapure Biopharma Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by UCB SA, H1 2018
Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2018
Primary Immune Deficiency (PID) - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Primary Immune Deficiency (PID), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Systemic Lupus Erythematosus (Sle) Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 28-Nov-2023 Price: US 3380 Onwards Pages: 109
Market Overview of Global Systemic Lupus Erythematosus (Sle) Drugs market:
According to our latest research, the global Systemic Lupus Erythematosus (Sle) Drugs market looks promising in the next 5 years. As of 2022, the global Systemic Lupus Erythematosus (Sle) Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents......
Autoimmune Drugs Industry Forecasts - China Focus
Published: 27-Nov-2023 Price: US 1800 Onwards Pages: 78
This study focuses on China's Autoimmune Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. Th......
Autoimmune Drugs Companies in China
Published: 27-Nov-2023 Price: US 1800 Onwards Pages: 71
This study focuses on China's Autoimmune Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of......
Autoimmune Drugs Markets in China
Published: 27-Nov-2023 Price: US 4000 Onwards Pages: 201
China's demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indu......
Autoimmune Collaboration and Licensing Deals 2016-2023
Published: 01-Oct-2023 Price: US 3995 Onwards Pages: 450
Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of autoimmune deals from 2016 to 2023.
The report includes coverage of the following autoimmune diseases:
Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Infla......
Global Autoimmune Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 29-Aug-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Autoimmune Drugs market:
According to our latest research, the global Autoimmune Drugs market looks promising in the next 5 years. As of 2022, the global Autoimmune Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Autoimmune Drugs market......
Global Autoimmune Drugs Market Insights, Forecast to 2029
Published: 14-Aug-2023 Price: US 4900 Onwards Pages: 92
Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by chronic inflammatory processes that activate the innate immune system and the production of antibodies that destroy host tissues. These inflammatory processes can be caused by genetic or environmental ......
Global Systemic Lupus Erythematosus (SLE) Drugs Market Insights, Forecast to 2029
Published: 14-Aug-2023 Price: US 4900 Onwards Pages: 75
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of ......
Global Systemic Lupus Erythematosus (Sle) Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
Published: 11-Jul-2023 Price: US 3260 Onwards Pages: 130
The Systemic Lupus Erythematosus (Sle) Drugs market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Systemic Lupus Erythematosus (Sle) Drugs industry, and breaks down according to the type, application, and consumption area of Systemic Lupus Erythematosus (Sle) Drugs. The report also introduces players in the industry from the per......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
